Sumatriptan 6 mg subcutaneous as aneffective migraine treatment in patients with cutaneous allodynia who historically fail to respond to oral triptans

摘要

The objective of the study was to assess the efficacy of 6 mg subcutaneous (SC) sumatriptan to treat migraine and the relationship between response of migraine and cutaneous allodynia in a population of migraine patients who historically failed to respond to oral triptan medications. This was an openlabel study consisting of patients with migraines who historically failed to respond to oral triptan medications. Forty-three patients were asked to treat three migraine attacks with 6 mg SC sumatriptan. The primary efficacy endpoint was the percentage of patients achievingrelief of headache at 2 h. Ninetyonepercent of the patients respondedto a single dose of SC sumatriptan6 mg. Fifty percent of allpatients were pain-free by 2 h andover 30% had a 24-h sustainedpain-free response. When administeredwithin 90 min from the onsetof migraine (i.e., during the developingphase of cutaneous allodynia),SC 6 mg sumatriptan provedto be effective despite the occurrenceof allodynia in a group ofpatients, who historically had failedto respond to oral triptan medications.These findings suggest thatthe window of opportunity to treatallodynic patients with injectabletriptans may be longer (up to 2 h)than with oral triptans (up to 1 h).